文献速递胃肠动力与功能性疾病

随机临床试验与荟萃分析:美沙拉秦治疗肠易激综合征对胃肠道症状及直肠免疫活性生物标志物的影响

Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.
PubMed 文献 · Aliment Pharmacol Ther · 2022-08-08

这项随机双盲安慰剂对照多中心试验纳入181例肠易激综合征(IBS)患者,美沙拉秦2400mg每日一次治疗8周,主要终点达标率美沙拉秦组36% vs 安慰剂组30%(p=0.40),腹胀改善更明显(p=0.02)。事后荟萃分析显示美沙拉秦对IBS症状无效应,黏膜贴片技术检测的直肠免疫活性无法预测应答。

要点

  • 美沙拉秦2400mg每日一次治疗8周,主要终点达标率36% vs 30%(p=0.40),无效。
  • 美沙拉秦组腹胀改善更明显(p=0.02),但荟萃分析显示对IBS症状无效应。
  • 黏膜贴片技术检测的直肠免疫活性不能预测美沙拉秦应答。

核心结论

  • 美沙拉秦在减少IBS症状方面无效。
  • 通过黏膜贴片技术检测的直肠免疫活性不能预测对美沙拉秦更高的应答机会。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组、多中心试验,纳入符合罗马III标准的IBS受试者,治疗8周,美沙拉秦2400mg或安慰剂每日一次。
  • 共纳入181例患者,91例接受美沙拉秦,90例接受安慰剂。
  • 事后补充了美沙拉秦治疗IBS的随机安慰剂对照试验的荟萃分析。

主要发现

  • 主要终点为干预期间≥50%周数达到IBS症状满意缓解的总体评估,美沙拉秦组32例(36%)达标 vs 安慰剂组27例(30%)达标(p=0.40)。
  • 与IBS亚型或感染后症状起病相关的应答率无差异。
  • 美沙拉秦组腹胀减少更明显(p=0.02)。
  • 荟萃分析显示美沙拉秦对IBS症状无效应。
  • 黏膜贴片技术检测指标均不能预测对美沙拉秦的应答,且未发现干预对免疫标志物水平的影响存在差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-grade immune activation in the gut is a potential treatment target in irritable bowel syndrome (IBS). AIMS: To determine improvement in IBS symptoms after mesalazine treatment, and the utility of measures of immune activity in the rectal mucosa METHODS: This was a randomised, double-blind, placebo-controlled, parallel-arm, multicentre trial in subjects with IBS (Rome III criteria), with an eight-week treatment period of mesalazine 2400 mg or plcebo once-daily. The primary endpoint was the global assessment of satisfactory relief of IBS symptoms in ≥50% of weeks during intervention. IBS symptoms were also measured with the IBS severity scoring system; immune activity was measured by mucosal patch technology. A post hoc meta-analysis of randomised placebo-controlled trials of mesalazine in IBS was added. RESULTS: Of 181 included patients, 91 received mesalazine and 90 received placebo. The primary endpoint was met by 32 (36%) patients after mesalazine and 27 (30%) after placebo (p = 0.40). There were no differences in response rates related to IBS subtype or post-infection symptom onset. More reduction of abdominal bloating was noted in the mesalazine group (p = 0.02). The meta-analysis showed no effect of mesalazine on IBS symptoms. No mucosal patch technology measure could predict response to mesalazine, and found no differences in the effects of intervention on levels of immune markers. CONCLUSIONS: Mesalazine is ineffective in reducing IBS symptoms. Rectal measures of immune activity by the mucosal patch technology cannot predict a higher chance of response to mesalazine.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Castro Tejera V, Öhman L, Aabakken L, et al. Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity. Aliment Pharmacol Ther. 2022. PMID: 35942522. doi:10.1111/apt.17182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。